Drug Information

Drug General Information
Drug ID
D05VEV
Former ID
DNC006566
Drug Name
Ac-hPhe-Leu-Ala-LeuVSMe
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528196]
Formula
C29H46N4O6S
Canonical SMILES
CC(C)CC(C=CS(=O)(=O)C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(<br />CCC1=CC=CC=C1)NC(=O)C
InChI
1S/C29H46N4O6S/c1-19(2)17-24(15-16-40(7,38)39)32-27(35)21(5)30-29(37)26(18-20(3)4)33-28(36)25(31-22(6)34)14-13-23-11-9-8-10-12-23/h8-12,15-16,19-21,24-26H,13-14,17-18H2,1-7H3,(H,30,37)(H,31,34)(H,32,35)(H,33,36)/b16-15+/t21-,24+,25-,26-/m0/s1
InChIKey
WUQZWLVEKPBGGU-WXIXLNPNSA-N
PubChem Compound ID
11556056
Target and Pathway
Target(s) Cathepsin B Target Info Inhibitor [528196]
Cathepsin S Target Info Inhibitor [528196]
KEGG Pathway Lysosome
Antigen processing and presentationhsa04142:Lysosome
Phagosome
Antigen processing and presentation
Tuberculosis
NetPath Pathway TCR Signaling Pathway
IL2 Signaling PathwayNetPath_22:Leptin Signaling Pathway
IL2 Signaling Pathway
Reactome Collagen degradation
Trafficking and processing of endosomal TLR
Assembly of collagen fibrils and other multimeric structures
MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway
Degradation of the extracellular matrix
MHC class II antigen presentation
WikiPathways Class I MHC mediated antigen processing & presentation
Trafficking and processing of endosomal TLR
References
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.